USANA Health Sciences has a decent ROE of 12%, indicating efficient capital utilization. Despite stagnant earnings and a declining net income rate, analysts foresee a slight improvement in earnings growth, potentially offering relief to shareholders.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing